GSK is one of the world’s leading research-based pharmaceutical and healthcare companies. As part of its overall strategy to increase growth, reduce risk and improve long-term financial performance,
The agreement provides Takeda access to Presage’s proprietary CIVO technology platform to enable identification of novel oncology drug combinations in solid tumors. Under the agreement, Presage and Takeda
The MoU confirms PICI and PsiOxus’s interest in working together to develop and test novel "armed" oncolytic viral constructs utilizing PsiOxus’ proprietary T-SIGn platform and manufacturing capabilities. Under
These include head and neck, anal, and cervical cancer, as well as anal, vaginal, penile, vulvar and cervical pre-cancerous neoplasias. PDS0101 is based on the company’s proprietary Versamune®
CCP-08 is the third extended-release product being developed for Vernalis by Tris Pharma for the US prescription cough-cold market. The first product, Tuzistra XR was approved by the
This 100-patient study, known as the Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF (INDIE-HFpEF) study, will be sponsored by Duke Clinical Research Institute (DCRI) as the
KAR5585 is being developed for the treatment of pulmonary arterial hypertension (PAH) and other rare diseases marked by extensive fibrosis. KAR5585 is a first-in-class, selective inhibitor of tryptophan
All 29 member states included in the decentralized procedures supported approval of the product. The authorities’ approval formally acknowledges that Synthon’s glatiramer acetate is regarded therapeutically equivalent to
The licensing agreement also encompasses rights for all therapeutic indications to cirmtuzumab, an anti-ROR1 monoclonal antibody that is currently in a clinical trial for patients with chronic lymphocytic
The product, Arcoral Tab, which EUSA plans to rebrand under the Caphosol name, is a topical oral agent used in the treatment of conditions resulting in reduced salivary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.